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OBJECTIVES: Two billion people worldwide have been infected
with hepatitis B virus and approximately 400 million present
chronic disease. Part of chronically infected patients with HBV
develop cirrhosis and liver failure. Two strategies are adopted for
treatment of chronic hepatitis B: a) use of interferon (conven-
tional and pegylated) for a limited timeframe and b) use of
nucleoside/tide analogs for a determined period. This analysis
aims to assess the Incremental cost-utility ratio for peginterferon-
alfa-2a (40 KD) versus lamivudine, for treatment of HBeAg-
positive and HBeAg-negative patients with hepatitis B, from the
perspective of the National Health Service. METHODS: A
Markov model was used to estimate the clinical and economic
impact of the incorporation of peginterferon-alfa-2a (40 KD).
Clinical stages were based on liver histology, cirrhotic decompen-
sation, liver cancer and liver transplantation. Costs were esti-
mated based on resource utilization described in a Delphi panel
with experts. Response and seroconversion rates with peginter-
feron alfa-2a (40 KD) were 36% for HBeAg-negative, and 32%
for HBeAg-positive patients. For lamivudine, rates were 23%
and 19%, respectively. Data concerning the quality-of-life were
extracted from the international literature, due to the lack of
local data. A lifetime horizon was assumed. RESULTS: The ICER
(peginterferon-alfa-2a vs. lamivudine) was R$ 20,192 HBeAg-
negative patients, and R$ 33,749 for HBeAg-positive patients,
assuming a discount rate of 3%. A probabilistic sensitivity analy-
sis was conducted using second-order Monte Carlo simulation.
Tested parameters were costs per stage, treatment costs, discount
rate, and responsiveness to treatment. The 95% conﬁdence inter-
val for the ICER ranged from R$ 12,275 to R$ 35,048 for
HBeAg-negative patients, and R$ 17,771 to R$ 67,430 for
HBeAg-positive patients. CONCLUSION: The study suggests
that therapy with peginterferon-alfa-2a (40 KD) has a robust and
favorable cost-utility ratio in the Brazilian public health system
for both serological proﬁles.
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OBJECTIVES: WHO estimates suggests that there are nearly
38,6 millions HIV/AIDS infected persons worldwide. Some epi-
demiological data suggests around 30% of HIV-infected patients
are also infected by HCV, what would lead to 12 million patients
co-infected with HIV and HCV. Recently, a multicenter, random-
ized controlled trial (APRICOT Torriani et al. 2004) has demon-
strated the efﬁcacy of alphapeginterferon-2a (40KD) + ribavirin
(PEG + RBV) treatment and its superiority to alphainterferon-
2a + ribavirin (IFN + RBV) for the treatment of chronic hepatitis
C in HIV-infected patients. However, incremental cost-
effectiveness ratios have not been established yet for this group of
patients for the private payer perspective in Brazil. METHODS:
A cost-utility analysis was conducted attempting to estimate
costs and outcomes in long term timeframe for PEG + RBV,
IFN + RBV and no speciﬁc treatment for co-infected patients. To
project the disease path, a markov model based on published
literature was constructed. Clinical practice and medical resource
utilization was assessed by a Delphi panel with Brazilian experts.
Both costs and outcomes were discounted at a 3% annual rate.
Payer perspective was adopted regarding direct costs for a life-
time perspective. The model was submitted to a univariate and a
probabilistic sensitivity analysis, beyond Monte Carlo second-
order simulation, to evaluate uncertainties on ICER estimates.
RESULTS: The ICER for the treatment with PEG + RBV com-
pared with IFN + RBV was R$36,645 per QALY with a 95%
conﬁdence interval between R$22,504 to R$64,175. The ICER
for the treatment with PEG + RBV compared with no speciﬁc
treatment was R$28,912 per QALY and the 95% conﬁdence
interval between R$18,768 to R$50,572. CONCLUSION: The
study results suggest that the treatment with alfapeginterferon-2a
(40 KD) can be considered a cost-effective alternative, as it
improves quality and quantity of life regarding other options and
it offers an incremental cost-effectiveness ratio robust and accept-
able for the private payer in Brazil.
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OBJECTIVES: The purpose of this study was to evaluate the
affordability of Antimalarial Drugs using real world data from
private pharmacies, missionary and government hospitals in
Benin city, Nigeria. METHODS: The mean  SD of prices that
patients prescribed Antimalarials in Benin city pay for a standard
regimen when they have malaria was collected from private
pharmacies, missionary and government hospitals. Minimum
wage was obtained directly from the least paid unskilled govern-
ment workers.The data was used to develop a stochastic monte
carlo model that calculates affordability of an Antimalarial drug
(in days’ wages). Two markov models that use 2007 data to
project prices of antimalarial drugs and monthly minimum wages
into the future using inﬂation rates, prices of antimalarials, per-
centage increase in wages and a ﬁxed discount rate of 5% were
also built. Results of the markov models serve as inputs for the
monte carlo simulations so that affordability can thus be pro-
jected into the future for the next 10 years. All three models
reported 1000 observations averaged over 10 repeated simula-
tions. RESULTS: Branded Antimalarial drugs were less afford-
able compared to the lowest priced generic versions (p < 0.0001).
Branded chloroquine tablets were 290% more expensive than the
unbranded and the least paid unskilled government worker
would need to spend about 20 days’ wages to treat malaria with
artemether 80 mg/ml injection. Antimalarials from missionary
and government hospitals were not necessarily more affordable
than those bought in private pharmacies.Peadiatric dihydroarte-
misinin 160 mg/80 ml may become 182% less affordable in 2012
and 226% less affordable by 2017 (p < 0.0001). All Antimalari-
als studied exhibited a similar trend. Sensitivity analyses showed
that these ﬁndings were robust. CONCLUSION: Unless deliber-
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